Increased circulating Tfh to Tfr ratio in chronic renal allograft dysfunction: a pilot study

BMC Immunology

Table 3 Stratified analysis of cTfh to cTfr ratio

		Stable group	CAD group	Total	P-value
Group 1	N	10	5	15	1.000 (Group 1 vs Group 2)
Group 1	Percentage	66.7%	33.3%		0.081 (Group 1 vs Group 3)
Group 2	N	12	6	18	0.038 (Group 1 vs Group 4)
Group 2	Percentage	66.75	33.3%		0.067 (Group 2 vs Group 3)
Group 3	N	6	11	17	0.030 (Group 2 vs Group 4)
Group 3	Percentage	35.3%	64.7%		0.718 (Group 3 vs Group 4)
Group 4	N	5	12	17
Group 4	Percentage	29.4%	70.6%
Total	N	33	34	67
Total	Percentage	49.3%	50.7%
P-value	0.046

Group 1 (cTfh to cTfr ratio ≤ 16); Group 2 (16 < cTfh to cTfr ratio ≤ 35); Group 3 (35 < cTfh to cTfr ratio ≤ 60); Group 4 (cTfh to cTfr ratio > 60). P-value < 0.05 was shown in bold

ISSN: 1471-2172